CTLA-4 delivers inhibitory signals to DCs, resulting in the down-regulation of CD80 and CD86 expression on these cells. 1,2 T REG-specific deficiency of CTLA-4 impairs the in vivo and in vitro ...
Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...
By combining CTLA-4 inhibition with PD-1 and VEGFA blockade, CS2009 may further enhance benefits for patients with low or negative PD-L1 expression, who respond poorly to PD-(L)1 therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback